OMEROS CORP (NASDAQ:OMER), Up By 22.08% ($1.22) After BUYINS.NET SqueezeTrigger Report Released on Wednesday, February 1st 2012
February 17, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Wednesday, February 1st 2012 at 09:16:00 PST stating that OMEROS CORP (NASDAQ:OMER) was expected to be Up After it crossed above its SqueezeTrigger Price of 5.53 on Wednesday, February 1st 2012. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=omer&id=238390
From August 2009 to January 2012, an aggregate amount of 10844579 shares of OMER have been shorted for a total dollar value of $54222895. The OMER SqueezeTrigger price of $5.53 is the volume weighted average price that all shorts are short in shares of OMER. There is still approximately $488,741 of potential short covering in shares of OMER.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .
OMEROS CORP (NASDAQ:OMER) - Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products focused on inflammation and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The companys lead PharmacoSurgery product candidate, OMS103HP, is in Phase III clinical program for evaluating OMS103HPs safety and ability to improve postoperative joint function and reduce pain following arthroscopic anterior cruciate ligament; and to reduce pain and improve postoperative joint function following arthroscopic meniscectomy surgery. Its PharmacoSurgery product candidates also include OMS302, which completed its Phase I/II clinical trial for use during ophthalmological procedures; and OMS201, which is in Phase I/II clinical trial for use during urological surgery. The company also engages in developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARγ) agonists for the treatment and prevention of addiction to substances of abuse. Its pipeline of preclinical product development programs include MASP-2 program for developing proprietary mannan-binding lectin-associated serine protease-2 antibody therapies to treat disorders caused by complement-activated inflammation; PDE10 program for developing proprietary compounds to treat schizophrenia and other psychotic disorders; PDE7 program for developing proprietary compounds to treat movement disorders; and GPCR program for the de-orphanization of orphan G protein-coupled receptors. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.
The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net